Hormone Therapy for Stage 2 Breast Cancer: 73 Real Stories

R S

Patient Info: R S | Stage II

R S was still receiving treatment and was taking Femara after choosing a plan that included mastectomy, radiation therapy, and hormonal therapy.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Mia's Patient Story

Patient Info: Mia | Stage II

Mia completed treatment and continued to manage its physical, emotional, and financial effects.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Nelly's Patient Story

Patient Info: Nelly | Stage II

Nelly said she was in remission after mastectomy, chemotherapy, and radiation and remained on hormone therapy.

Our Cancer StoriesRead more →

Erika

Patient Info: Erika | Stage II

Erika said she was cancer free as of November 2023 after completing mastectomy, chemotherapy, and targeted therapy, while hormone therapy continued.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Graciela's Patient Story

Patient Info: Graciela | Stage II

Graciela remained in treatment with tamoxifen after lumpectomy for stage 2 breast cancer; radiation therapy had also been recommended.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Camila's Survivor Story

Patient Info: Camila, Female, 40s | Stage II

Camila completed the recommended treatment plan and moved into survivorship, focusing on her daughter, family travel and returning to work.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Lilibeth's Survivor Story

Patient Info: Lilibeth | Stage II

Lilibeth described her stage 2 breast cancer as being in remission after completing most treatment and remained on hormone therapy.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Sylvie's Patient Story

Patient Info: Sylvie, Female, 40s | Stage II

Biomarkers: Hormone-sensitive breast cancer

Sylvie completed treatment for breast cancer and later treatment for recurrence, with a continued emphasis on screening, resilience, and life after treatment.

Fondation ARCRead more →

Stage II breast cancer, neoadjuvant chemotherapy, breast-conserving surgery, and hormone therapy story

Patient Info: Anonymized, Female, Under 40 | Stage II

After Stage II breast cancer diagnosed at age 38 in July 2007, she completed 4 cycles of neoadjuvant chemotherapy, breast-conserving surgery with no lymph node spread, and continued monthly hormone therapy while feeling well and returning to softball.

Stage II Breast Cancer: Alba's Patient Story

Patient Info: Alba, Female, 50s | Stage II

Alba was undergoing Stage II breast cancer care, had chosen modern medicine after seeking a second opinion and trying alternative approaches, and was on hormone therapy while focusing on recovery.

Our Cancer StoriesRead more →

Stage II Invasive Lobular Carcinoma: Alma's Patient Story

Patient Info: Alma, Female | Stage II

Alma had Stage II invasive lobular carcinoma treated with lumpectomy, chemotherapy, radiation, and planned 10 years of tamoxifen, then found a local recurrence 4.5 years after diagnosis.

Lobular Breast Cancer AllianceRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage II

Biomarkers: Genetic testing negative; Oncotype DX score 27; MammaPrint low risk; ER-positive

Tanya had Stage II ER-positive breast cancer with a large lobular tumor found on MRI, underwent bilateral mastectomy with immediate reconstruction, completed 4 rounds of chemotherapy, and started tamoxifen.

Lobular Breast Cancer AllianceRead more →

Stage II BRCA2 Breast Cancer: Rachel's Patient Story

Patient Info: Rachel Zitofsky, Female, Under 40 | Stage II

Biomarkers: BRCA2 mutation

Rachel was doing well 4.5 years after Stage II breast cancer diagnosis and continued tamoxifen; her BRCA2 result also led her sister to expanded testing and preventive care.

Memorial Sloan KetteringRead more →

Stage II Breast Cancer: Renée's Survivor Story

Patient Info: Renée, Female, Under 40 | Stage II

Renée described her health as stable and her treatment as working. She remained on a long-term hormone-based anti-cancer regimen and was still healing from reconstruction complications rather than describing herself as cancer-free.

The Patient StoryRead more →

Stage II Breast Cancer: Wendi's Survivor Story

Patient Info: Wendi Kushner | Stage II

Biomarkers: Triple-positive

After the clinical trial, lumpectomy pathology showed a complete pathological response with no residual cancer in the breast or lymph nodes.

MD AndersonRead more →

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Stage II Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40 | Stage II

Biomarkers: Hormone receptor-positive; HER2-negative; BRCA inherited gene mutations negative

As of April 2026, Jenna had completed pregnancy-associated chemotherapy and double mastectomy for Stage II HR-positive, HER2-negative breast cancer with 1 involved lymph node, did not need radiation, and was on hormone therapy for 10 years.

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

Stage IIA ER/PR-positive mucinous breast cancer: tamoxifen plus cryoablation with no recurrence

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: ER/PR strongly positive, HER2 negative; CA15-3 and CEA remained normal during follow-up.

At approximately 32 months after cryoablation, the treated area had decreased to a less distinct 0.7 cm scar-like region, with no evidence of recurrence in either breast, axillae, or distant sites.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →